Francesco Branciforti

Dr. Francesco Branciforti

Politecnico di Torino, Department of Electronics and Telecommunications, corso Duca degli Abruzzi, 24, I-10129, Torino, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in Expert Systems with Applications
Verified
Journal Article
Open access
Massimo SalviMassimo Salvi
Massimo Salvi
FBFrancesco Branciforti
Francesco Branciforti
FMFilippo Molinari
Filippo Molinari
Kristen MeiburgerKristen Meiburger
Kristen Meiburger

5 March 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Federica VeroneseFederica Veronese
Federica Veronese
FBFrancesco Branciforti
Francesco Branciforti
Elisa ZavattaroElisa Zavattaro
Elisa Zavattaro
VTVanessa Tarantino
Vanessa Tarantino
VRValentina Romano
Valentina Romano
PSPaola Savoia
Paola Savoia
Background. The use of teledermatology has spread over the last years, especially during the recent SARS-Cov-2 pandemic. Teledermoscopy, an extension of teledermatology, consists of consulting dermoscopic images, also transmitted through smartphones, to remotely diagnose skin tumors or other dermatological diseases. The purpose of this work was to verify the diagnostic validity of images acquired with an inexpensive smartphone microscope (NurugoTM), employing convolutional neural networks (CNN) to classify malignant melanoma (MM), melanocytic nevus (MN), and seborrheic keratosis (SK). Methods. The CNN, trained with 600 dermatoscopic images from the ISIC (International Skin Imaging Collaboration) archive, was tested on three test sets: ISIC images, images acquired with the NurugoTM, and images acquired with a conventional dermatoscope. Results. The results obtained, although with some limitations due to the smartphone device and small data set, were encouraging, showing comparable results to the clinical dermatoscope and up to 80% accuracy (out of 10 images, two were misclassified) using the NurugoTM demonstrating how an amateur device can be used with reasonable levels of diagnostic accuracy. Conclusion. Considering the low cost and the ease of use, the NurugoTM device could be a useful tool for general practitioners (GPs) to perform the first triage of skin lesions, aiding the selection of lesions that require a face-to-face consultation with dermatologists.

8 June 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
FBFrancesco Branciforti
Francesco Branciforti
Massimo SalviMassimo Salvi
Massimo Salvi
FDFilippo D'Agostino
Filippo D'Agostino
FMFrancesco Marzola
Francesco Marzola
SCSara Cornacchia
Sara Cornacchia
Kristen MeiburgerKristen Meiburger
Kristen Meiburger
Recent years have ushered in a transformative era in in vitro modeling with the advent of organoids, three-dimensional structures derived from stem cells or patient tumor cells. Still, fully harnessing the potential of organoids requires advanced imaging technologies and analytical tools to quantitatively monitor organoid growth. Optical coherence tomography (OCT) is a promising imaging modality for organoid analysis due to its high-resolution, label-free, non-destructive, and real-time 3D imaging capabilities, but accurately identifying and quantifying organoids in OCT images remain challenging due to various factors. Here, we propose an automatic deep learning-based pipeline with convolutional neural networks that synergistically includes optimized preprocessing steps, the implementation of a state-of-the-art deep learning model, and ad-hoc postprocessing methods, showcasing good generalizability and tracking capabilities over an extended period of 13 days. The proposed tracking algorithm thoroughly documents organoid evolution, utilizing reference volumes, a dual branch analysis, key attribute evaluation, and probability scoring for match identification. The proposed comprehensive approach enables the accurate tracking of organoid growth and morphological changes over time, advancing organoid analysis and serving as a solid foundation for future studies for drug screening and tumor drug sensitivity detection based on organoids.

26 October 2023 in Skin Research and Technology
Verified
Journal Article
Open access
FBFrancesco Branciforti
Francesco Branciforti
Kristen MeiburgerKristen Meiburger
Kristen Meiburger
Elisa ZavattaroElisa Zavattaro
Elisa Zavattaro
Federica VeroneseFederica Veronese
Federica Veronese
VTVanessa Tarantino
Vanessa Tarantino
Massimo SalviMassimo Salvi
Massimo Salvi
Background: The quality of dermoscopic images is affected by lighting conditions, operator experience, and device calibration. Color constancy algorithms reduce this variability by making images appear as if they were acquired under the same conditions, allowing artificial intelligence (AI)‐based methods to achieve better results. The impact of color constancy algorithms has not yet been evaluated from a clinical dermatologist's workflow point of view. Here we propose an in‐depth investigation of the impact of an AI‐based color constancy algorithm, called DermoCC‐GAN, on the skin lesion diagnostic routine. Methods: Three dermatologists, with different experience levels, carried out two assignments. The clinical experts evaluated key parameters such as perceived image quality, lesion diagnosis, and diagnosis confidence. Results: When the DermoCC‐GAN color constancy algorithm was applied, the dermoscopic images were perceived to be of better quality overall. An increase in classification performance was observed, reaching a maximum accuracy of 74.67% for a six‐class classification task. Finally, the use of normalized images results in an increase in the level of self‐confidence in the qualitative diagnostic routine. Conclusions: From the conducted analysis, it is evident that the impact of AI‐based color constancy algorithms, such as DermoCC‐GAN, is positive and brings qualitative benefits to the clinical practitioner.

2 June 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Federica VeroneseFederica Veronese
Federica Veronese
VTVanessa Tarantino
Vanessa Tarantino
Elisa ZavattaroElisa Zavattaro
Elisa Zavattaro
FBFrancesca Biacchi
Francesca Biacchi
Chiara AiroldiChiara Airoldi
Chiara Airoldi
PSPaola Savoia
Paola Savoia
Background: Due to the COVID-19 pandemic, teledermoscopy has been increasingly used in the remote diagnosis of skin cancers. In a study conducted in 2020, we demonstrated a potential role of an inexpensive device (NurugoTM Derma) as a first triage to select the skin lesions that require a face-to-face consultation with dermatologists. Herein, we report the results of a novel study that aimed to better investigate the performance of NurugoTM. Objectives: (i) verify whether the NurugoTM can be a communication tool between the general practitioner (GP) and dermatologist in the first assessment of skin lesions, (ii) analyze the degree of diagnostic–therapeutic agreement between dermatologists, (iii) estimate the number of potentially serious diagnostic errors. Methods: One hundred and forty-four images of skin lesions were collected at the Dermatology Outpatient Clinic in Novara using a conventional dermatoscope (instrument F), the NurugoTM (instrument N), and the latter with the interposition of a laboratory slide (instrument V). The images were evaluated in-blind by four dermatologists, and each was asked to make a diagnosis and to specify a possible treatment. Results: Our data show that F gave higher agreement values for all dermatologists, concerning the real clinical diagnosis. Nevertheless, a medium/moderate agreement value was obtained also for N and V instruments and that can be considered encouraging and indicate that all examined tools can potentially be used for the first screening of skin lesions. The total amount of misclassified lesions was limited (especially with the V tool), with up to nine malignant lesions wrongly classified as benign. Conclusions: NurugoTM, with adequate training, can be used to build a specific support network between GP and dermatologist or between dermatologists. Furthermore, its use could be extended to the diagnosis and follow-up of other skin diseases, especially for frail patients in emergencies, such as the current pandemic context.

26 May 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
Federica VeroneseFederica Veronese
Federica Veronese
VTVanessa Tarantino
Vanessa Tarantino
Elisa ZavattaroElisa Zavattaro
Elisa Zavattaro
FBFrancesca Biacchi
Francesca Biacchi
Chiara AiroldiChiara Airoldi
Chiara Airoldi
PSPaola Savoia
Paola Savoia
Background Due to the COVID-19 pandemic, teledermoscopy has been increasingly used in the remote diagnosis of skin cancers. In a study conducted in 2020, we demonstrated a potential role of an inexpensive device (NurugoTM Derma) as a first triage to select the skin lesions that require a face-to-face consultation with dermatologists. Herein, we report the results of a novel study that aims to better investigate the performance of NurugoTM. Objectives i) verify whether the NurugoTM can be a communication tool between the General Practitioner (GP) and dermatologist in the first assessment of skin lesions; ii) analyze the degree of diagnostic-therapeutic agreement between dermatologists; iii) estimate the number of potentially serious diagnostic errors. Methods One hundred forty-four images of skin lesions were collected at the Dermatology Outpatient Clinic in Novara using a conventional dermatoscope (instrument F), the NurugoTM (instrument N), and the latter with the interposition of a laboratory slide (instrument V). The images were evaluated in-blind by four dermatologists, and each was asked to make a diagnosis and to specify a possible treatment. Results: Our data show that F gave higher agreement values for all dermatologists, concerning the real clinical diagnosis. Nevertheless, a medium/moderate agreement value was obtained also for N and V instruments and that can be considered encouraging and indicate that all examined tools can potentially be used for the first screening of skin lesions. The total amount of misclassified lesions was limited (especially with the V tool), with up to nine malignant lesions wrongly classified as benign. Conclusions NurugoTM, with adequate training, can be used to build a specific support network between GP and dermatologist or between dermatologists. Furthermore, its use could be extended to the diagnosis and follow-up of other skin diseases, especially for frail patients in emergencies such as the current pandemic context.